A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
Samantha Mary Jaglowski
No relevant relationships to disclose
Jeffrey Alan Jones
No relevant relationships to disclose
Joseph M. Flynn
No relevant relationships to disclose
Leslie A. Andritsos
No relevant relationships to disclose
Kami J. Maddocks
No relevant relationships to disclose
Kristie A. Blum
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose
Susan Michelle Geyer
No relevant relationships to disclose
Jennifer Ann Woyach
No relevant relationships to disclose
Amy J Johnson
No relevant relationships to disclose
Nyla A. Heerema
No relevant relationships to disclose
Erin Molnar
No relevant relationships to disclose
Mona Stefanos
No relevant relationships to disclose
Susan Devlin
Employment or Leadership Position - Pharmacyclics
Tasheda Navarro
Employment or Leadership Position - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Ann M. Lowe
Employment or Leadership Position - Pharmacyclics
Eric Hedrick
Employment or Leadership Position - Pharmacyclics
John C. Byrd
No relevant relationships to disclose